EUVIMEDEUVIMED entdecken
Vergleichsstudie

Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN

Ohad Atia iD, Chagit Friss, Gili Focht, Ramit Magen Rimon iD, Natan Ledderman, Shira Greenfeld, Amir Ben-Tov, Yiska Loewenberg Weisband, Eran Matz, Yuri Gorelik, Yehuda Chowers, Iris Dotan und 1 weitere

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae067 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Ohad Atia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jeru…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Gastrointestinal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In this nationwide study, our objective was to compare the durability of first-line biologics in ulcerative colitis (UC), categorized into monotherapy and combotherapy with immunomodulators.

Methods

We utilized data from the nationwide epi-IIRN cohort from 2005 to 2020. Durability was defined as consistent treatment without surgery. Comparisons were based on stringent propensity score-matching.

Results

We included 15 111 patients with UC, of whom 2322 (15%) received biologics, with a median follow-up of 7.0 years (interquartile range, 3.8-11.0). The durability rate was similar between pediatric-onset and adults after 1 and 5 years from initiation of treatment (72% and 43% vs 71% and 43%, respectively; P = .8). Durability of adalimumab vs infliximab after 1 or 5 years was similar, whether prescribed as monotherapy (65%/46% vs 63%/33%, respectively; n = 182 matched pairs, P = .3) or combotherapy (78%/56% vs 91%/58%, respectively; n = 46 matched pairs, P = .4). Durability of infliximab was higher as combotherapy (85%/50%) vs monotherapy (69%/42%; n = 174 matched pairs, P = .007), while it was similar for adalimumab (80%/52% vs 74%/52%; n = 53 matched pairs, P = .4). The durability rate was similar for vedolizumab monotherapy (77%/56%) compared with adalimumab monotherapy (69%/52%; n = 125 matched patients, P = .1), and infliximab monotherapy (73%/55% vs 62%/44%; n = 78 matched patients, P = .1). However, combotherapy of antitumor necrosis factors (TNFs) had longer durability than vedolizumab (85%/50% vs 75%/43%, respectively; n = 131 matched pairs, P = .02).

Conclusion

After 5 years of treatment, 43% of the patients with UC sustained their first biologic, with similar durability in pediatric and adult-onset onset disease. Anti-TNFs had similar durability to vedolizumab and superior durability when prescribed as combotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsGastrointestinal AgentsHumansMaleFemaleAdultChildInfliximabAdalimumabAdolescentFollow-Up StudiesYoung AdultMiddle AgedDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

adalimumabdurabilityinfliximabulcerative colitisvedolizumab

Substanzen

InfliximabBiological ProductsAdalimumabGastrointestinal Agents

Autor:innen und Institutionen

  • Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Pediatric Gastroenterology & Nutrition Institute, Ruth Rappaport Children's Hospital, Rambam Health Care Campus and the Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
  • Meuhedet Health Services, Tel-Aviv, Israel.
  • Kahn-Sagol-Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Clalit Health Services, Clalit Research Institute, Tel-Aviv, Israel.
  • Leumit Health Services, Tel-Aviv, Israel.

ORCID-Profile: Ohad Atia, Ramit Magen Rimon

Förderung

  • Helmsley Charitable Trust

Zitieren

APA

Atia, O., Friss, C., Focht, G., Magen Rimon, R., Ledderman, N., Greenfeld, S., Ben-Tov, A., Loewenberg Weisband, Y., Matz, E., Gorelik, Y., Chowers, Y., Dotan, I., & Turner, D. (2025). Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae067

Vancouver

Atia O, Friss C, Focht G, Magen Rimon R, Ledderman N, Greenfeld S, et al. Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae067

BibTeX
@article{Atia2025,
  author = {Atia, Ohad and Friss, Chagit and Focht, Gili and Magen Rimon, Ramit and Ledderman, Natan and Greenfeld, Shira and Ben-Tov, Amir and Loewenberg Weisband, Yiska and Matz, Eran and Gorelik, Yuri and Chowers, Yehuda and Dotan, Iris and Turner, Dan},
  title = {Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae067}
}
Kostenlos starten →